Page 53 - Read Online

Page 338 Genvigir et al. J Transl Genet Genom 2020;4:320-55 I http://dx.doi.org/10.20517/jtgg.2020.37

Ref. [65] [24]

Clinical outcomes No association of SLCO2B1*3 variant with diarrhea No association of SLCO2B1 c.-71T>C variant with DGF or AR

Pharmacokinetics No association of SLCO2B1*3 variant with MPA pharmacokinetics No association of SLCO2B1 c.-71T>C variant with MPA C/D

Immunosuppressive regimen Tacrolimus Corticosteroids At day 28 EC-MPS Tacrolimus Corticosteroids One-year follow-up

87 adult patients (Japan) MMF

Population 97 adult patients (Brazil) AcMPAG: acyl-MPA-glucuronide; AR: allograft rejection; AUC: area under the concentration-time curve; C/D: trough dose-adjusted concentration; DGF: delayed graft function; EC-MPS: enteric- confirmed by Varnell et al. [27] in a case-control study with children and young adult kidney transplant recipients. On the other hand, CYP2C8 rs11572076GG genotype was associated with reduced risk of leukopenia (GG vs. GA; OR: 0.14,

Study design Prospective Prospective coated mycophenolate sodium salt; eGFR: estimated glomerular filtration rate; MMF: mycophenolate mofetil; MPA: mycophenolic acid; MPAG: MPA-7-O-glucuronide UGT2B7 and UGT1A8 in AcMPAG production, while UGT1A1, UGT1A7 and UGT1A10 plays a minor role in MPA glucuronidation [1,9,31] . UGT2B7 is expressed in a broad range of human tissues including liver, small intestine, and kidney [32] . between this UGT1A1 polymorphism

Allele frequency SLCO2B1*3: 30% c.-71C: 42%

rs2306168 (SLCO2B1*3, 1457C>T) rs2851069 (c.-71T>C) UGT1A1 and UGT1A7

Variant CYP2C8*3 variant was also low (9%) in these cohorts. UGT1A1, UGT1A7, UGT1A8, UGT1A9 and UGT2B7

Gene SLCO2B1 findings. isoforms.